Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PIKFYVE | Q9Y2I7 | 11/20 | 0.50 |
| ▸ | FES | P07332 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | FRK | P42685 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30312330 | 1.00 | KDM4E (0.55) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL23272148 | 0.94 | KDM4E (0.51) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL30312329 | 0.94 | KDM4E (0.51) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL30312419 | 0.92 | MAPT (0.57) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL21054975 | 0.92 | MAPT (0.57) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL23272117 | 0.92 | KDM4E (0.57) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL30312322 | 0.92 | KDM4E (0.57) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL23272155 | 0.90 | KDM4E (0.55) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL30312323 | 0.90 | KDM4E (0.55) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL23272152 | 0.89 | KDM4E (0.54) | KDM4EMAPTLMNAHPGDPIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11603372-B2 | Compounds and therapeutic uses thereof | VIOGEN BIOSCIENCES, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | TARDBP, PIKFYVE, FUS | KDM4E 788/4885MAPT 33/4885LMNA 2725/4885 |
| US-11603372-B2 | Compounds and therapeutic uses thereof | IL15, IL17A, IL2 | KDM4E 3881/4885MAPT 2341/4885LMNA 1857/4885 |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | IL15, IL17A, IL2 | KDM4E 3881/4885MAPT 2341/4885LMNA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.